Adapted risk stratification and intensive chemotherapy abrogate the poor prognosis of pediatric B acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21): a National cohort analysis.

This letter to the editor published in the journal Leukemia & Lymphoma discusses a study conducted on pediatric patients in Ireland with a specific genetic alteration called intrachromosomal amplification of chromosome 21 (iAMP21) in B acute lymphoblastic leukemia (B-ALL). The study found that patients with iAMP21 benefited from more intensive chemotherapy and that minimal residual disease (MRD) was a reliable predictor of outcome. The study also provides detailed clinical and biological characteristics of the Irish pediatric iAMP21 B-ALL cohort. The article emphasizes the importance of accurate diagnosis for risk stratification and appropriate treatment initiation in patients with iAMP21-positive B-ALL. [Extracted from the article]